v3.26.1
Condensed Consolidated Statements Of Cash Flows (Unaudited) - USD ($)
$ in Millions
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Operating Activities    
Net Income (Loss) $ (29) $ (63)
Non-cash reconciliation adjustments:    
Unrealized (gains) losses on derivative instruments (Note 2) 352 103
Depreciation, amortization and accretion (Note 16) 158 141
Nuclear decommissioning trust funds (gain) loss, net (excluding interest and fees) (Note 6) (85) (44)
Nuclear fuel amortization (Note 7) 46 44
Deferred income taxes (34) (66)
Stock-based compensation (Note 13) 69 27
Other (Note 16) 35 7
Changes in assets and liabilities:    
Accounts receivable (59) (103)
Inventory, net 10 78
Other assets 14 15
Accounts payable and accrued liabilities 20 (57)
Accrued interest 107 12
Collateral received (posted), net (35) (58)
Cash settlement of stock-based awards (Note 13) (495) 0
Other liabilities (47) (101)
Net cash provided by (used in) operating activities 27 (65)
Investing Activities    
Property, plant and equipment expenditures (Note 7) (181) (51)
Nuclear fuel expenditures (Note 7) (66) (50)
Nuclear decommissioning trust funds investment purchases (Note 6) (195) (1,201)
Nuclear decommissioning trust funds investment sale proceeds (Note 6) 173 1,186
Cornerstone Acquisition, net (Note 17) (2,568) 0
Other 13 2
Net cash provided by (used in) investing activities (2,824) (114)
Financing Activities    
Debt issuances (Note 10) 4,000 0
Debt repayments (Note 10) (1,215) (9)
Deferred financing costs (58) (9)
Revolving credit facility borrowings (Note 10) 500 75
Revolving credit facility repayments (Note 10) (500) (5)
Share repurchases (Note 15) (298) (103)
Tax payments related to net-settled stock-based awards (Note 13) (140) 0
Other (6) 0
Net cash provided by (used in) financing activities 2,283 (51)
Net increase (decrease) in cash and cash equivalents and restricted cash and cash equivalents (514) (230)
Beginning of period cash and cash equivalents and restricted cash and cash equivalents 752 365
End of period cash and cash equivalents and restricted cash and cash equivalents $ 238 $ 135